SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following 131I therapy-Reference-Cited by-同舟云学术

SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following 131I therapy

Published:2023-01 Issue:1 Volume:13 Page:101-110
ISSN:2190-7188
Container-title:Health and Technology
language:en
Short-container-title:Health Technol.

Author:

Abuqbeitah Mohammad,Demir Mustafa,Sağer Sağit,Asa Sertaç,Işıkcı Nazenin Ipek,Sönmezoğlu Kerim

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s12553-022-00718-y.pdf

Reference51 articles.

1. Fugazzola L, Elisei R, Fuhrer D, et al. European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. Eur Thyroid J. 2019;8(5):227–45. https://doi.org/10.1159/000502229.

2. Cayir D, Mine A. Radioiodine Therapy of Malignant Thyroid Diseases. Radionuclide Treatments. 2017;21.

3. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer-Treatment: State of the Art. Int J Mol Sci. 2017;18(6):1292. Published 2017 Jun 1. https://doi.org/10.3390/ijms18061292.

4. Wyszomirska A. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur. 2012;15(2):120–123. Published 2012 Aug 28.

5. Verburg FA, Giovanella L, Iakovou I, Konijnenberg MW, Langsteger W, Lassmann M, Mihailovic J, Luster M. I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignhematologicalconvenient" truth? Eur J Nucl Med Mol Imaging. 2018;45(13):2247–9. https://doi.org/10.1007/s00259-018-4184-z. Epub 2018 Oct 8 PMID: 30298378.